VALISEEK  

Drug repositioning for lung cancer  

Sector

Cancer therapeutics

Stage

Clinical Phase II

Funding needed

£4.9M

Country

UK

VAL401, a repositioned drug, reducing development time, regulatory hurdles and costs

The product could be <5 years away from market and 1-2 years from a potential IPO

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar